1. IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
- Author
-
Singh S, Xiao Z, Bavisi K, Roszik J, Melendez BD, Wang Z, Cantwell MJ, Davis RE, Lizee G, Hwu P, Neelapu SS, Overwijk WW, and Singh M
- Subjects
- Animals, Cell Line, Tumor, Cytokines immunology, Cytokines metabolism, Humans, Immune Checkpoint Inhibitors immunology, Interleukin-1alpha metabolism, Kaplan-Meier Estimate, Melanoma, Experimental immunology, Mice, Inbred C57BL, Myeloid-Derived Suppressor Cells immunology, Myeloid-Derived Suppressor Cells metabolism, Neutrophils immunology, Neutrophils metabolism, Signal Transduction drug effects, Signal Transduction immunology, Tumor Microenvironment drug effects, Tumor Microenvironment immunology, Mice, Drug Resistance, Neoplasm immunology, Immune Checkpoint Inhibitors therapeutic use, Immunotherapy methods, Interleukin-1alpha immunology, Melanoma, Experimental therapy
- Abstract
Inflammation has long been associated with cancer initiation and progression; however, how inflammation causes immune suppression in the tumor microenvironment and resistance to immunotherapy is not well understood. In this study, we show that both innate proinflammatory cytokine IL-1α and immunotherapy-induced IL-1α make melanoma resistant to immunotherapy. In a mouse melanoma model, we found that tumor size was inversely correlated with response to immunotherapy. Large tumors had higher levels of IL-1α, Th2 cytokines, polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), and regulatory T cells but lower levels of IL-12, Th1 cytokines, and activated T cells. We found that therapy with adenovirus-encoded CD40L (rAd.CD40L) increased tumor levels of IL-1α and PMN-MDSCs. Blocking the IL-1 signaling pathway significantly decreased rAd.CD40L-induced PMN-MDSCs and their associated PD-L1 expression in the tumor microenvironment and enhanced tumor-specific immunity. Similarly, blocking the IL-1 signaling pathway improved the antimelanoma activity of anti-PD-L1 Ab therapy. Our study suggests that blocking the IL-1α signaling pathway may increase the efficacy of immunotherapies against melanoma., (Copyright © 2021 by The American Association of Immunologists, Inc.)
- Published
- 2021
- Full Text
- View/download PDF